Crohn's Disease Clinical Trials in Chicago, Illinois

4 studies are recruiting for crohn's disease in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    University of Chicago Medical Center ( Site 5066), Chicago, Illinois
    Locations
    499 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06430801 on ClinicalTrials.gov

  2. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    Rush University Medical Center-Site Number: 8400015, Chicago, Illinois
    Locations
    461 in total
    Run by
    Sanofi

    See if you can join NCT07184931 on ClinicalTrials.gov

  3. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

    Stage
    Phase 3
    Ages
    18 to 70
    Site
    Rush University Medical Center, Chicago, Illinois
    Locations
    183 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06937099 on ClinicalTrials.gov

  4. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    University of Chicago Medical Center /ID# 267400, Chicago, Illinois
    Locations
    255 in total
    Run by
    AbbVie

    See if you can join NCT06548542 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.